Ms. Logan led the company for more than 12 years, and according to Tom D’Alonzo, chairman of Salix’s board of directors, Ms. Logan took “Salix from an early-stage commercial company with a market capitalization of approximately $200 million, one product and less than $25 million in annual revenues, to a leading gastroenterology-focused specialty pharmaceutical company with a multi-billion dollar market capitalization, more than 20 products and over $1 billion in annual revenues.”
Mr. D’Alonzo will be appointed acting CEO. Ms. Logan will remain a consultant to the company.
More articles on GI/endoscopy:
Global endoscopy market to reach $47B by 2020: 8 key trends
GI Dynamics names Michael Dale president & CEO
Diagnostic Endoscopy Center’s Dr. Stuart Waldstreicher honored
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.